Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Beijing Wantai Biological Pharmaceutical Co., Ltd. (abbreviated as Wantai Biological) was established in 1991 and is a high-tech enterprise engaged in the research and production of biological diagnostic reagents and vaccines. The company pursues "contributing to the cause of human health" and is committed to transforming biotechnology achievements into high-quality products to serve the public. The company has seven subsidiaries, covering multiple fields such as enzyme immunoassay, colloidal gold, chemiluminescence, nucleic acid testing, biochemistry, vaccines, and quality control products. In 2005, with the approval of the Ministry of Science and Technology, Yangshengtang Wantai Biology and Xiamen University jointly established the National Center for Infectious Disease Diagnostic Reagents and Vaccine Engineering Technology Research (NIDVD). The center has built an indispensable bridge between product development and industrialization, becoming an industry incubator that effectively undertakes relevant research and development achievements both domestically and internationally. It has accelerated the speed of diagnostic reagents and vaccine research and development products entering the market, shortened the product conversion cycle, and made significant progress in China's infectious disease diagnostic reagents and vaccine industry. Beijing Wantai Biopharmaceutical Co., Ltd. adheres to the development philosophy of "science oriented, health oriented", Adhere to Our mission is to strive for survival through quality and development through technological innovation. We are committed to contributing to the cause of human health and will definitely write a glorious chapter in the development history of diagnostic reagents and vaccines in China. Wantai Biotechnology attaches great importance to the construction of research teams and research platforms. We have hundreds of different professional and technical talents, as well as enzyme immunoassay, chemiluminescence, rapid diagnosis, nucleic acid diagnosis, virus isolation and large-scale cultivation, genetic engineering, monoclonal antibodies and multi antibodies Preparation and large-scale purification technology platforms. The company relies on its strong technical strength and sharp and rapid market response ability to meet clinical and disease monitoring needs during major outbreaks of infectious diseases in the country, such as SARS (SARS), H5N1 avian influenza, influenza A, and EV71 hand, foot, and mouth disease. Wantai Biotechnology has undertaken multiple scientific research projects, including the National 863 Plan, the Ninth Five Year Plan, the Tenth Five Year Plan, the Eleventh Five Year Plan for Science and Technology Support, the Eleventh Five Year Plan and the Twelfth Five Year Plan for Major Infectious Disease Science and Technology, as well as key research projects by the Ministry of Education and provinces (cities), to promote the rapid transformation of scientific research achievements and achieve their industrialization. In 2008, he was awarded the "National High tech Industrialization Ten Year Achievement Award" by the National Development and Reform Commission. The company attaches great importance to cooperation and academic exchange with research institutes, and maintains a long-term and stable cooperative relationship with Xiamen University. In 2005, with the approval of the Ministry of Science and Technology, the National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD) was jointly established with Xiamen University. The center has built an indispensable bridge between product development and industrialization, becoming an industry incubator that effectively undertakes relevant research and development achievements both domestically and internationally. It has accelerated the speed of diagnostic reagents and vaccine research and development products entering the market, shortened product conversion cycles, improved social and economic benefits, and made significant progress in China's infectious disease diagnostic reagents and vaccine industry. The biopharmaceutical joint laboratory established in cooperation with Xiamen University has achieved multiple innovative scientific research results with clear application prospects over the past decade: 1. The third-generation HIV diagnostic reagent has won the second prize of the National Science and Technology Progress Award and the first prize of the Ministry of Education's Science and Technology Progress Award; 2. The discovery and clinical application of the dominant conformational antigenic determinants of hepatitis E virus have won the second prize of the National Technical Invention Award and the first prize of the Fujian Provincial Science and Technology Award; 3. HIV antibody rapid diagnostic reagent won the Beijing Science and Technology Progress Award; 4. The T lymphocyte leukemia virus antibody reagent has won the second prize of the Ministry of Education's Science and Technology Progress Award and has been recognized as a key project of the National Torch Plan; 5. "HIV recombinant antigen and series of diagnostic reagents" was identified as "National Torch Plan Project"; 6. The global innovative completion of clinical trials of hepatitis E vaccine has achieved a new breakthrough in China's high-quality original genetic engineering virus vaccine. Wantai Biological products are sold to more than 30 countries, including the United States, the United Kingdom, Germany, France, Spain, Malaysia, the Netherlands, Indonesia, Iran, India, Brazil, the Philippines, Thailand, the Czech Republic, Sudan, Egypt, Peru, etc. Its superior product performance has been widely praised by foreign customers. |
| Headquarter | Beijing |
| Establish Date | 4/24/1991 |
| Listed Code | 603392.SH |
| Listed Date | 4/29/2020 |
| Chairman | Qiu Zixin. |
| CEO | Qiu Zixin. |
| Website | www.ystwt.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
